[儿童肾母细胞瘤的保留器官手术]

[Organ-sparing surgery for nephroblastoma in children].

作者信息

Ismail-zade R S, Kochubinskiĭ D V, Shimanskiĭ A T, Nazaruk S I, Rutskaia E A, Begin I V, Fedorova A S, Savva N N, Vydanov O I

出版信息

Vopr Onkol. 2012;58(4):502-6.

PMID:23607205

Abstract

We present the results of 53 stage I-III nephroblastoma pediatric patients treated in Belarusia from 2005 to 2010. All the patients received adjuvant chemotherapy (according to SIOP WT 2001 protocol), surgery (complete or partial nephrectomy) and neoadjuvant chemotherapy. The prolonged adjuvant chemotherapy was proposed in patients with good response as a cytoreductive measure enabling organ-sparing surgery. Five-year event-free survival was 91+/-6% in complete and 89+/-9% in partial nephrectomy recipients (p=0,64). Our experience suggest the feasibility of prolonged adjuvant chemoradiotherapy in patients with good clinical response and no contraindications for complete nephrectomy.

摘要

我们展示了2005年至2010年在白俄罗斯接受治疗的53例I - III期肾母细胞瘤儿科患者的结果。所有患者均接受了辅助化疗（根据SIOP WT 2001方案）、手术（根治性或部分肾切除术）和新辅助化疗。对于反应良好的患者，建议延长辅助化疗作为一种减瘤措施，以实现保留器官的手术。根治性肾切除术患者的五年无事件生存率为91±6%，部分肾切除术患者为89±9%（p = 0.64）。我们的经验表明，对于临床反应良好且无根治性肾切除术禁忌证的患者，延长辅助放化疗是可行的。